NCT01324323View on ClinicalTrials.gov

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 1, 2011

Primary Completion Date

February 1, 2012

Study Completion Date

March 1, 2012

Conditions
Hematologic MalignancyMalignant Lymphoma
Interventions
DRUG

Romidepsin

14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.

DRUG

Rifampin

600 mg oral once daily on Days 4-8

Trial Locations (3)

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Canon Research Institute, Nashville

W1G6AD

Sarah Cannon Research UK, London

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY